Drug Profile
ELND 004
Alternative Names: ELND004Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Elan Corporation
- Developer Perrigo
- Class Small molecules
- Mechanism of Action Integrin alpha4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Autoimmune-disorders in Europe (PO)
- 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
- 28 Feb 2009 Phase-I clinical trials in Autoimmune disorders in Europe (PO)